论文部分内容阅读
酪氨酸蛋白激酶是多种肿瘤最常见的生长因子受体 ,是信号转导过程中的首要关键步骤。通过阻断酪氨酸激酶可破坏肿瘤细胞的信号传递 ,从而达到治疗肿瘤的目的。近年来 ,有关酪氨酸激酶抑制剂的研究非常活跃 ,出现了诸如C2 2 5 ,CI10 33,PKI 16 6 ,OSI 774 ,ZD1839,STI5 71等一批新药。OSI 774和ZD1839已使难治性非小细胞肺癌患者的病情减缓。C2 2 5可提高化、放疗的疗效 ,STI5 71在慢性粒细胞性白血病和胃肠间质性肿瘤治疗中取得了突破性进展。酪氨酸激酶抑制剂已成为抗肿瘤疗法中的一个新的有希望的侯选药物。
Tyrosine protein kinases are the most common growth factor receptors for many tumors and are the number one key step in signal transduction. By blocking tyrosine kinase can destroy the signal transmission of tumor cells, so as to achieve the purpose of treatment of tumors. In recent years, studies on tyrosine kinase inhibitors have been very active. A number of new drugs such as C225, CI1033, PKI166, OSI774, ZD1839 and STI571 have emerged. OSI 774 and ZD1839 have slowed the progression of patients with refractory non-small cell lung cancer. C2 2 5 can improve the curative effect of chemotherapy and radiotherapy. STI5 71 has made breakthrough progress in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. Tyrosine kinase inhibitors have emerged as a promising new drug candidate in antitumor therapy.